The NCI-MATCH trial: lessons for precision oncology

被引：60

作者：

O'Dwyer, Peter J. ^{[1
]}

Gray, Robert J. ^{[2
]}

Flaherty, Keith T. ^{[3
]}

Chen, Alice P. ^{[4
]}

Li, Shuli ^{[2
]}

Wang, Victoria ^{[2
]}

McShane, Lisa M. ^{[5
]}

Patton, David R. ^{[6
]}

Tricoli, James V. ^{[4
]}

Williams, P. Mickey ^{[7
]}

Iafrate, A. John ^{[3
]}

Sklar, Jeffrey ^{[8
]}

Mitchell, Edith P. ^{[9
]}

Takebe, Naoko ^{[4
]}

Sims, David J. ^{[7
]}

Coffey, Brent ^{[6
]}

Fu, Tony ^{[7
]}

Routbort, Mark ^{[10
]}

Rubinstein, Larry V. ^{[5
]}

Little, Richard F. ^{[4
]}

Arteaga, Carlos L. ^{[11
]}

Marinucci, Donna ^{[12
]}

Hamilton, Stanley R. ^{[13
]}

Conley, Barbara A. ^{[14
]}

Harris, Lyndsay N. ^{[14
]}

Doroshow, James H. ^{[4
]}

机构：

[1] Univ Penn, Philadelphia, PA 19104 USA

[2] ECOG ACRIN Biostat Ctr, Dana Farber Canc Inst, Boston, MA USA

[3] Massachusetts Gen Hosp, Canc Ctr, Boston, MA USA

[4] NCI, Div Canc Treatment & Diag, Bethesda, MD USA

[5] NCI, Biometr Res Program, Div Canc Treatment & Diag, Bethesda, MD USA

[6] NCI, Ctr Biomed Informat & Informat Technol, Bethesda, MD USA

[7] Frederick Natl Lab Canc Res, Frederick, MD USA

[8] Yale Univ, New Haven, CT USA

[9] Thomas Jefferson Univ Hosp, Philadelphia, PA USA

[10] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[11] UT Southwestern Simmons Comprehens Canc Ctr, Dallas, TX USA

[12] ECOG ACRIN Canc Res Grp, Philadelphia, PA USA

[13] City Hope Natl Med Ctr, Duarte, CA USA

[14] NCI, Canc Diag Program, Div Canc Treatment & Diag, Bethesda, MD USA

来源：

NATURE MEDICINE | 2023年 / 29卷 / 6期

关键词：

PHASE-II; SOLID TUMORS; CANCERS; BRAF; VEMURAFENIB; INHIBITION; VALIDATION; TRAMETINIB; MUTATIONS; THERAPY;

D O I：

10.1038/s41591-023-02379-4

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The NCI-MATCH (Molecular Analysis for Therapy Choice) trial () was launched in 2015 as a genomically driven, signal-seeking precision medicine platform trial-largely for patients with treatment-refractory, malignant solid tumors. Having completed in 2023, it remains one of the largest tumor-agnostic, precision oncology trials undertaken to date. Nearly 6,000 patients underwent screening and molecular testing, with a total of 1,593 patients (inclusive of continued accrual from standard next-generation sequencing) being assigned to one of 38 substudies. Each substudy was a phase 2 trial of a therapy matched to a genomic alteration, with a primary endpoint of objective tumor response by RECIST criteria. In this Perspective, we summarize the outcomes of the initial 27 substudies in NCI-MATCH, which met its signal-seeking objective with 7/27 positive substudies (25.9%). We discuss key aspects of the design and operational conduct of the trial, highlighting important lessons for future precision medicine studies.

引用

页码：1349 / 1357

页数：9

共 50 条

[1] Impact of NCI-MATCH: a Nationwide Oncology Precision Medicine Trial
Khan, Sabrina S.
Chen, Alice P.
Takebe, Naoko
EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2019, 4 (04): : 251 - 258
[2] The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design
Flaherty, Keith T.
Gray, Robert
Chen, Alice
Li, Shuli
Patton, David
Hamilton, Stanley R.
Williams, Paul M.
Mitchell, Edith P.
Iafrate, A. John
Sklar, Jeffrey
Harris, Lyndsay N.
McShane, Lisa M.
Rubinstein, Larry, V
Sims, David J.
Routbort, Mark
Coffey, Brent
Fu, Tony
Zwiebel, James A.
Little, Richard F.
Marinucci, Donna
Catalano, Robert
Magnan, Rick
Kibbe, Warren
Weil, Carol
Tricoli, James, V
Alexander, Brian
Kumar, Shaji
Schwartz, Gary K.
Meric-Bernstam, Funda
Lih, Chih-Jian
McCaskill-Stevens, Worta
Caimi, Paolo
Takebe, Naoko
Datta, Vivekananda
Arteaga, Carlos L.
Abrams, Jeffrey S.
Comis, Robert
O'Dwyer, Peter J.
Conley, Barbara A.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2020, 112 (10): : 1021 - 1029
[3] Tumor-Specific Activity of Precision Medicines in the NCI-MATCH Trial
Zhou, Ivvone
Plana, Deborah
Palmer, Adam C.
CLINICAL CANCER RESEARCH, 2024, 30 (04) : 786 - 792
[4] Considerations of developing an NGS assay for clinical applications in precision oncology: The NCI-MATCH NGS assay experience
Lih, Chih-Jian
Takebe, Naoko
CURRENT PROBLEMS IN CANCER, 2017, 41 (03) : 201 - 211
[5] Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor NCI-MATCH Subprotocol EAY131-Y Nonrandomized Trial
Kalinsky, Kevin
Hong, Fangxin
McCourt, Carolyn K.
Sachdev, Jasgit C.
Mitchell, Edith P.
Zwiebel, James A.
Doyle, L. Austin
McShane, Lisa M.
Li, Shuli
Gray, Robert J.
Rubinstein, Larry V.
Patton, David
Williams, Paul M.
Hamilton, Stanley R.
Conley, Barbara A.
O'Dwyer, Peter J.
Harris, Lyndsay N.
Arteaga, Carlos L.
Chen, Alice P.
Flaherty, Keith T.
JAMA ONCOLOGY, 2021, 7 (02) : 271 - 278
[6] Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial
Mansfield, A. S.
Wei, Z.
Mehra, R.
Shaw, A. T.
Lieu, C. H.
Forde, P. M.
Drilon, A. E.
Mitchell, E. P.
Wright, J. J.
Takebe, N.
Sharon, E.
Hovelson, D.
Tomlins, S.
Zeng, J.
Poorman, K.
Malik, N.
Gray, R. J.
Li, S.
McShane, L. M.
Rubinstein, L., V
Patton, D.
Williams, P. M.
Hamilton, S. R.
Conley, B. A.
Arteaga, C. L.
Harris, L. N.
O'Dwyer, P. J.
Chen, A. P.
Flaherty, K. T.
NPJ PRECISION ONCOLOGY, 2022, 6 (01)
[7] Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH)
Flaherty, Keith T.
Gray, Robert J.
Chen, Alice P.
Li, Shuli
McShane, Lisa M.
Patton, David
Hamilton, Stanley R.
Williams, P. Mickey
Iafrate, A. John
Sklar, Jeffrey
Mitchell, Edith P.
Harris, Lyndsay N.
Takebe, Naoko
Sims, David J.
Coffey, Brent
Fu, Tony
Routbort, Mark
Zwiebel, James A.
Rubinstein, Larry V.
Little, Richard F.
Arteaga, Carlos L.
Comis, Robert
Abrams, Jeffrey S.
O'Dwyer, Peter J.
Conley, Barbara A.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (33) : 3883 - 3894
[8] Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Results of the NCI-MATCH Trial Subprotocol H
Salama, April K. S.
Li, Shuli
Macrae, Erin R.
Park, Jong-In
Mitchell, Edith P.
Zwiebel, James A.
Chen, Helen X.
Gray, Robert J.
McShane, Lisa M.
Rubinstein, Larry V.
Patton, David
Williams, P. Mickey
Hamilton, Stanley R.
Armstrong, Deborah K.
Conley, Barbara A.
Arteaga, Carlos L.
Harris, Lyndsay N.
O'Dwyer, Peter J.
Chen, Alice P.
Flaherty, Keith T.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (33) : 3895 - 3904
[9] Innovative trial design in precision oncology
Tsimberidou, Apostolia M.
Muller, Peter
Ji, Yuan
SEMINARS IN CANCER BIOLOGY, 2022, 84 : 284 - 292
[10] Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2-Amplified Tumors: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol J
Connolly, Roisin M.
Wang, Victoria
Hyman, David M.
Grivas, Petros
Mitchell, Edith P.
Wright, John J.
Sharon, Elad
Gray, Robert J.
McShane, Lisa M.
Rubinstein, Larry V.
Patton, David R.
Williams, P. Mickey
Hamilton, Stanley R.
Wang, Jue
Wisinski, Kari B.
Tricoli, James V.
Conley, Barbara A.
Harris, Lyndsay N.
Arteaga, Carlos L.
O'Dwyer, Peter J.
Chen, Alice P.
Flaherty, Keith T.
CLINICAL CANCER RESEARCH, 2024, 30 (07) : 1273 - 1280

← 1 2 3 4 5 →